<br>Lymphoma Australia is excited to let you know that eligible patients with Mycosis Fungoides – a type of cutaneous (skin) T-cell lymphoma now have another treatment option. As of November 1st, 2024, LEDAGA® gel is available on Australia’s Pharmaceutical Benefits Scheme (PBS). This is a huge step forward for adults with Mycosis Fungoides. The active ingredient of this topical treatment is Chlormethine Hydrochloride, which is an alkylating agent. This means it’s a type of chemotherapy in a gel form and is applied directly to the affected skin.
Having this treatment listed on the PBS provides a more affordable and convenient option for eligible patients to manage their condition.
To qualify for this treatment, patients must meet certain criteria:
- the disease should be at an early stage (IA, IB, or IIA), confirmed by a biopsy
- affect only a limited body surface area (up to 25%)
- patient must be over the age of 18.
<br>Only dermatologists or hematologists can prescribe LEDAGA® and with special approval, patients can get up to four weeks of treatment per prescription.
Healthcare professionals are encouraged to familiarise themselves with LEDAGA’s® prescribing details, including proper use and precautions. More information can be found in the product’s official documentation. This is a promising development for improving care and access for those living with MF-CTCL.
